Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL-2: PRV-3279 in systemic lupus erythematosus
CTR20232381Phase 2Terminated
- Sponsor
- Provention Bio
- Start
- Mar 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PRV-3279 in systemic lupus erythematosus (SLE), sponsored by Provention Bio. Started Mar 2022; status: terminated.
02
Drugs
PRV-3279
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20232381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232381.